| pubmed-article:19208420 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19208420 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19208420 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:19208420 | lifeskim:mentions | umls-concept:C0040028 | lld:lifeskim |
| pubmed-article:19208420 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:19208420 | lifeskim:mentions | umls-concept:C1517942 | lld:lifeskim |
| pubmed-article:19208420 | lifeskim:mentions | umls-concept:C1707491 | lld:lifeskim |
| pubmed-article:19208420 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:19208420 | pubmed:dateCreated | 2009-3-31 | lld:pubmed |
| pubmed-article:19208420 | pubmed:abstractText | Cytotoxic agents like Hydroxyurea, Busulfan and Interferon-alpha are to date the most commonly used therapeutic approaches in Essential Thrombocythemia (ET). However, few data on the efficacy and safety of these agents in the long-term are currently available. We report a retrospective analysis of the long-term outcome of 386 consecutive ET patients, followed at single Institution for a median follow-up of 9.5 years (range, 3-28.5). Cytoreductive therapy was administered to 338 patients (88%), obtaining a response in 86% of cases. Forty-five patients (12%) experienced a thrombosis. Among baseline characteristics, only history of vascular events prior to ET diagnosis predicted a higher incidence of thrombosis. Evolution in acute leukemia/myelofibrosis occurred in 6 (1,5%) and 20 (5%) patients, and was significantly higher in patients receiving sequential cytotoxic agents. Overall survival was 38% at 19 years and was poorer for patients older than 60 years, with higher leukocytes count (>15 x 10(9)/L), hypertension and mellitus diabetes at ET diagnosis and for patients experiencing a thrombotic event during follow-up. Cytoreductive therapy was effective in decreasing platelet number with negligible toxicity; however, thrombocytosis control did not reduce the incidence of thrombosis and, for patients who received sequential therapies, the probability of disease evolution was higher and survival was poorer. | lld:pubmed |
| pubmed-article:19208420 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19208420 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19208420 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19208420 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19208420 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19208420 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19208420 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:19208420 | pubmed:issn | 1096-8652 | lld:pubmed |
| pubmed-article:19208420 | pubmed:author | pubmed-author:OttavianiEman... | lld:pubmed |
| pubmed-article:19208420 | pubmed:author | pubmed-author:TestoniNicole... | lld:pubmed |
| pubmed-article:19208420 | pubmed:author | pubmed-author:BaccaraniMich... | lld:pubmed |
| pubmed-article:19208420 | pubmed:author | pubmed-author:FiacchiniMaur... | lld:pubmed |
| pubmed-article:19208420 | pubmed:author | pubmed-author:VianelliNicol... | lld:pubmed |
| pubmed-article:19208420 | pubmed:author | pubmed-author:CataniLuciaL | lld:pubmed |
| pubmed-article:19208420 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:19208420 | pubmed:author | pubmed-author:PalandriFranc... | lld:pubmed |
| pubmed-article:19208420 | pubmed:author | pubmed-author:SalmiFederica... | lld:pubmed |
| pubmed-article:19208420 | pubmed:author | pubmed-author:LucchesiAless... | lld:pubmed |
| pubmed-article:19208420 | pubmed:author | pubmed-author:PolverelliNic... | lld:pubmed |
| pubmed-article:19208420 | pubmed:copyrightInfo | Copyright 2008 Wiley-Liss, Inc. | lld:pubmed |
| pubmed-article:19208420 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19208420 | pubmed:volume | 84 | lld:pubmed |
| pubmed-article:19208420 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19208420 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19208420 | pubmed:pagination | 215-20 | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:meshHeading | pubmed-meshheading:19208420... | lld:pubmed |
| pubmed-article:19208420 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19208420 | pubmed:articleTitle | Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. | lld:pubmed |
| pubmed-article:19208420 | pubmed:affiliation | Department of Hematology and Medical Oncology L. e A. Seràgnoli, St. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. | lld:pubmed |
| pubmed-article:19208420 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19208420 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19208420 | lld:pubmed |
